Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Tradition Meets Innovation -­ Greiner Bio-One Celebrates 50 Successful Years

Published: Friday, December 13, 2013
Last Updated: Thursday, December 12, 2013
Bookmark and Share
Company now has over 1,700 employees spread across seven production facilities.

This year marks the 50th anniversary of Greiner Bio-One GmbH. Over the past five decades, the business founded in Nürtingen, Germany, as Greiner Labortechnik has become an international high-tech company, but it has never lost sight of its modest SMB roots.

Combining tradition with innovation has created a globally successful technology partner for the diagnostic, pharmaceutical and biotechnology industries.

Greiner Labortechnik started out in 1963 in Nürtingen, producing the first plastic Petri dishes. A further production facility that opened in Austria in 1974 also initially manufactured Petri dishes.

In the 1980s, Greiner unveiled VACUETTE ­ the first evacuated blood collection system with a plastic safety cap ­ which can maintain a vacuum for at least 18 months.

This extremely important innovation was key in shaping the company’s further development. Another major breakthrough came in 1997 with the world’s first 1536 well microplate.

In 1988, an ultramodern 15,000 square metre injection moulding production facility opened in Frickenhausen, near Nürtingen. The company also invested in a new production site in the United States and, in 2001, Greiner Labortechnik became Greiner Bio-One International AG.

With a global turnover of 364 million euros, Greiner now has over 1,700 employees spread across seven production facilities and 24 subsidiaries in countries such as France, the Netherlands, Belgium, the United Kingdom, Japan, Hungary, the United States, Switzerland, Brazil, Thailand, China and India.

Based in the Austrian town of Kremsmünster, the Preanalytics division supplies hospitals, clinical laboratories, blood donation centres and the diagnostics industry with complete solutions for venous and capillary blood collection.

Innovations include safety products to protect against needlestick injuries and the VACUETTE PREMIUM tubes with a special screw cap that protect health service professionals against infections.

The division’s latest development is the VACUETTE TUBE TOUCH safety holder. When inserting the tube into the holder, a mechanism activates a safety cap to ensure risk-free blood collection.

The Diagnostics division focuses on DNA chip technology. Biochips provide conclusive proof of the specific genetic fingerprints of many different parameters in a single analysis. The CarnoCheck DNA chip, for example, detects traces of various animal species in food products.

A further significant Greiner Bio-One innovation is the PapilloCheck HPV test, which reliably identifies and flags up 24 strains of the human papillomavirus (HPV). This has taken Greiner Bio-One a big step forward in the early detection of a virus that is the main cause of cervical cancer.

Headed by managing director Heinz Schmid, the German headquarters of the BioScience division in Frickenhausen control all research and development activities in the Cell Culture, High-Throughput Screening and OEM product sectors for markets throughout the world.

Schmid, who started his career as a trainee at the company, sees the anniversary as more than simply an excuse for nostalgia. “I share my staff’s great pride when I see the trust placed in Greiner Bio-One products by scientists and doctors working in areas such as cancer research, virus diagnostics and vaccine production the world over. We are committed to always delivering optimum solutions with our innovations,” he says.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Big Plans and 40 Years of Experience
Rudi Vollmer becomes new Technical Managing Director of Greiner Bio-One GmbH, responsible for production and technology.
Tuesday, June 30, 2015
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!